Topic

Articles

Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.

Q&A With Javier Szwarcberg, MD, MPH, CEO of Spruce Biosciences

Partner at Simon-Kucher & Partners, leading its life sciences division in greater China

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthcare

Sadik Kassim is chief technology officer, Genomic Medicines for the Life Sciences companies at Danaher Corporation, which include Aldevron, Integrated DNA Technologies (IDT), SCIEX, Beckman Coulter Life Sciences, and Precision NanoSystems

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.

Three Key Steps to Unlocking mRNA’s Potential Beyond COVID-19

Pharm Exec speaks with Ambrogio about the struggles the industry faces in regard to developing cures for rare cancers, and how Bayer is using precision medicine to meet these challenges.

Q&A with Nelson Ambrogio, senior vice president, general manager Oncology US, Bayer Pharmaceuticals

Pharm Exec speaks with Adams about how his company developed a new medicine designed to meet migraine patients’ needs.

Q&A With Adrian Adams, chairman and chief executive officer of Impel Pharmaceuticals

Managing Vice President at the Philadelphia Office of Pariveda

Industry has shown it can overcome challenges en route to creating new therapies.

What the COVID-19 Vaccine Process Showed Us, and How It Can Impact the Future of Drug Development

Vice President of Analytics and Insights Management, Array

New mediums of technology must be utilized correctly to reap full benefits.

If Content Is King, Context Is the Power Behind the Throne

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

Q&A With Miruna Sasu, president and CEO, COTA, Inc.

Global Head of Thought Leadership, Decision Resources Group, Clarivate

With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.

Next-Gen Partnerships: The Ascent of Advanced Therapies  

Foster talks to Pharm Exec about why liver disease is on the rise, and Hepion’s new therapy, rencofilstat, in development to treat it.

R&D/Clinical Trials